Cancer News and Research

Latest Cancer News and Research

SAFC, Oncolytics Biotech sign commercial supply agreement for REOLYSIN

Oncolytics Biotech Inc. today announced that it has entered into a commercial supply agreement with SAFC, a Division of Sigma-Aldrich Corporation, for the commercial manufacture of REOLYSIN, Oncolytics proprietary reovirus.

11 May 2011

Symphogen to present second-generation Sympress platform at ESACT conference

Symphogen, a private biopharmaceutical company developing superior antibody therapeutics to treat cancer, infectious and autoimmune diseases, announced today that second-generation enhancements to the company's SYMPRESS manufacturing and quality control platform will be presented in an oral presentation entitled "Recombinant antibody mixtures; optimization of cell line generation and single-batch manufacturing processes" by Dr. Søren K. Rasmussen, Principal Scientist, Symphogen at the upcoming European Society for Animal Cell Technology conference in Vienna on May 17, 2011.

11 May 2011

Study: Many patients screened for colon cancer more often than recommended

Many patients are getting screened for colorectal cancer more often than guidelines recommend, hints a new study.

11 May 2011

Common tiny tropical fish plays a key role in new model for Cushing disease

A common, tiny tropical fish plays a key role in a new model for Cushing disease, giving researchers a powerful tool to conduct extensive searches for effective treatments for this serious hormonal disorder, testing up to 300 drugs weekly.

11 May 2011

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology. The results suggest moderate to severe rheumatoid arthritis patients treated with Cimzia, the only approved PEGylated anti-TNF, together with methotrexate, achieved a rapid response associated with improved long-term outcomes one year after treatment began.

11 May 2011

Majority of urban NYC women with hepatitis B do not receive education, subsequent care

According to new research at Columbia Presbyterian Medical Center, high rates of chronic hepatitis B infection are found in pregnant minority and immigrant women in the New York City area, and most of them do not receive education, appropriate follow-up testing or referral, which is considered the standard of care for all persons newly identified as HBV carriers.

11 May 2011

Inovio first quarter total revenue increases to $3.1 million for 2011

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2011.

11 May 2011

Adherence to disease-modifying drugs is low in patients with multiple sclerosis

Disease-modifying drugs (DMDs) are injected medications used to slow the progression of multiple sclerosis, and have been shown to reduce the frequency and severity of relapses. But according to a new study led by St. Michael's Hospital and the Institute for Clinical Evaluative Sciences, adherence to all DMDs is low, with less than half of patients, or 44 per cent, continually adherent after two years.

11 May 2011

Women with invasive breast cancer can benefit from new genomic test

A new genomic test combining multiple signatures - a patient's estrogen receptor status, endocrine therapy response, chemotherapy resistance and sensitivity - shows promise as a predictor of chemotherapy response and survival benefit in women with invasive breast cancer, according to research led by The University of Texas MD Anderson Cancer Center.

11 May 2011

Genentech submits vemurafenib NDA for BRAF V600 mutation-positive metastatic melanoma

Genentech, a member of the Roche Group, today announced that the company submitted a New Drug Application for vemurafenib to the U.S. Food and Drug Administration for people with BRAF V600 mutation-positive metastatic melanoma, and that Roche submitted a Marketing Authorization Application to the European Medicines Agency for vemurafenib in the same indication.

11 May 2011

BioAlliance Pharma enters license deal with Sosei to commercialize Loramyc in Japan

BioAlliance Pharma, a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced that it has entered into an exclusive licensing agreement with Sosei Co. Ltd. for commercialization rights in Japan for Loramyc muco-adhesive buccal tablet.

11 May 2011

Novel ultrasound-targeted microbubble-destruction technology advances cure for prostate cancer

Cancer researchers are a step closer to finding a cure for advanced prostate cancer after effectively combining an anti-cancer drug with a viral gene therapy in vivo using novel ultrasound-targeted microbubble-destruction (UTMD) technology.

11 May 2011

Sosei acquires rights to Loramyc in Japan from BioAlliance Pharma

Sosei Group Corporation, the biopharmaceutical company, today announces that Sosei Co., Ltd., its wholly owned Japanese subsidiary, acquired development and commercialization rights to Loramyc (miconazole Lauriad) in Japan from BioAlliance Pharma.

11 May 2011

Novel two-drug combination cures young patient with extensively drug-resistant tuberculosis

Belgian physicians report they have cured a young patient with extensively drug-resistant tuberculosis (XDR-TB) using a novel two-drug combination developed by researchers at Albert Einstein College of Medicine of Yeshiva University. The report, published in the Pediatric Infectious Disease Journal, marks the first known clinical use of this treatment for XDR-TB, the most deadly form of the disease.

11 May 2011

Shanghai Zhabei Health Bureau, CWRU sign 10-year research deal to study Chinese lifestyle

Case Western Reserve University School of Medicine has signed an unprecedented 10-year research agreement with the Shanghai Zhabei District Health Bureau to study how an increasingly westernized diet and a less active lifestyle are affecting the health of China's residents.

11 May 2011

Genetic test to identify women at higher risk of breast cancer could reduce risks associated with screening

Calculating individual genetic cancer risk and taking age into account could mean fewer women would need to be screened for breast cancer, according to research published in the British Journal of Cancer1.

11 May 2011

Plexxikon seeks vemurafenib marketing approval from FDA and EMA for melanoma treatment

Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced that applications for market approval for vemurafenib for the treatment of metastatic melanoma have been submitted to the U.S. Food and Drug Administration and the European Medicines Agency.

11 May 2011

Zebrafish research identifies undiscovered high-risk genetic features in T-cell acute lymphocytic leukemia

Leukemia is the most common childhood cancer; it also occurs in adults. Now researchers working with zebrafish at Huntsman Cancer Institute (HCI) at the University of Utah have identified previously undiscovered high-risk genetic features in T-cell acute lymphocytic leukemia (T-ALL), according to an article published online May 9, 2011, in the cancer research journal Oncogene.

11 May 2011

Second subject enrolled in human embryonic stem cell therapy trial for subacute thoracic spinal cord injury

Researchers at Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine and The Rehabilitation Institute of Chicago (RIC) recently enrolled their first subject in a national clinical research trial of a human embryonic stem cell-based therapy for participants with a subacute thoracic spinal cord injury.

11 May 2011

Protein critical to formation of new blood vessels could lead to therapies to starve cancerous tumors

UT Southwestern Medical Center researchers have discovered a protein that guides blood vessel development and eventually might lead to a treatment to keep cancer cells from spreading.

11 May 2011

Cancer News and Research

Latest Cancer News and Research

SAFC, Oncolytics Biotech sign commercial supply agreement for REOLYSIN

Symphogen to present second-generation Sympress platform at ESACT conference

Study: Many patients screened for colon cancer more often than recommended

Common tiny tropical fish plays a key role in new model for Cushing disease

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

Majority of urban NYC women with hepatitis B do not receive education, subsequent care

Inovio first quarter total revenue increases to $3.1 million for 2011

Adherence to disease-modifying drugs is low in patients with multiple sclerosis

Women with invasive breast cancer can benefit from new genomic test

Genentech submits vemurafenib NDA for BRAF V600 mutation-positive metastatic melanoma

BioAlliance Pharma enters license deal with Sosei to commercialize Loramyc in Japan

Novel ultrasound-targeted microbubble-destruction technology advances cure for prostate cancer

Sosei acquires rights to Loramyc in Japan from BioAlliance Pharma

Novel two-drug combination cures young patient with extensively drug-resistant tuberculosis

Shanghai Zhabei Health Bureau, CWRU sign 10-year research deal to study Chinese lifestyle

Genetic test to identify women at higher risk of breast cancer could reduce risks associated with screening

Plexxikon seeks vemurafenib marketing approval from FDA and EMA for melanoma treatment

Zebrafish research identifies undiscovered high-risk genetic features in T-cell acute lymphocytic leukemia

Second subject enrolled in human embryonic stem cell therapy trial for subacute thoracic spinal cord injury

Protein critical to formation of new blood vessels could lead to therapies to starve cancerous tumors

Understanding the DNA Damage Response in Innate Immunity eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in